Pathogenic EZH2 modulates lymphoid oncogenesis by epigenetic repression of tumor suppressors, orchestrating with lncRNAs, site-specific PTMs, affecting microenvironment and EBV-host interplay. The gene discussed is EZH2; the disease is neoplasm.